Drug Profile
Research programme: specifically-targeted antimicrobial peptides - Armata Pharmaceuticals
Alternative Names: C3CD-17; CD 17; MRSA STAMP; Sm STAMPLatest Information Update: 28 Feb 2020
Price :
$50
*
At a glance
- Originator C3 Jian
- Developer Armata Pharmaceuticals
- Class Antibacterials; Peptide fragments
- Mechanism of Action Microbiome modulators; Peptide modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Clostridium difficile infections; Methicillin-resistant Staphylococcus aureus infections; Skin and soft tissue infections
Most Recent Events
- 28 Feb 2020 No recent reports of development identified for preclinical development in Methicillin-resistant-Staphylococcus-aureus-infections in USA
- 28 Feb 2020 No recent reports of development identified for preclinical development in Skin-and-soft-tissue-infections in USA
- 28 Jan 2020 No recent reports of development identified for preclinical development in Clostridium-difficile-infections in USA (PO)